Earnings results for Corvus Pharmaceuticals (NASDAQ:CRVS)
Corvus Pharmaceuticals, Inc. is estimated to report earnings on 03/04/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.36. The reported EPS for the same quarter last year was $-0.38.
Analyst Opinion on Corvus Pharmaceuticals (NASDAQ:CRVS)
3 Wall Street analysts have issued ratings and price targets for Corvus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.00, predicting that the stock has a possible upside of 146.91%. The high price target for CRVS is $12.00 and the low price target for CRVS is $4.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Corvus Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $8.00, Corvus Pharmaceuticals has a forecasted upside of 146.9% from its current price of $3.24. Corvus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Corvus Pharmaceuticals (NASDAQ:CRVS)
Corvus Pharmaceuticals does not currently pay a dividend. Corvus Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Corvus Pharmaceuticals (NASDAQ:CRVS)
In the past three months, Corvus Pharmaceuticals insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $4,849,999.00 in company stock and sold $0.00 in company stock. 45.12% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. 60.80% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Corvus Pharmaceuticals (NASDAQ:CRVS
Earnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($1.45) to ($1.56) per share. The P/E ratio of Corvus Pharmaceuticals is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Corvus Pharmaceuticals is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Corvus Pharmaceuticals has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here